Abbott smartens up its smartphone-based ICM with more accurate detection

The loop recorder connects directly to the user's smartphone via Bluetooth. (Image: Abbott)

Abbott has launched a new, smarter version of its small implantable monitor for detecting irregular heartbeats that the company says now reduces the rate of false detection by 97%.

About the size of a paperclip, the Confirm Rx insertable cardiac monitor connects directly to a smartphone app via Bluetooth, to offer continuous remote detection of arrhythmias without the need for additional transmitter hardware.

The loop recording device, which has been cleared by the FDA and received a CE mark, is placed just under the skin above the heart during an outpatient procedure. Additionally, Abbott’s mobile app is available in nearly 40 languages.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Abbott rolls out smartphone-connected ICM in the U.S.

Abbott first picked up the Confirm Rx monitor and its smartphone app through its $25 billion acquisition of St. Jude Medical in January 2017. The device made its international commercial debuts later that year, including in Europe and the U.S.

The tracker is aimed at the estimated 33 million people living with the most common irregular heartbeat, atrial fibrillation, with many going undiagnosed.

RELATED: The top 10 medtech companies of 2024 | Abbott Laboratories

It’s also designed for people with active lifestyles, and offers 24/7 monitoring compared to devices that need to be removed and placed in a charging station, which can lead to gaps in the detection of sporadic and infrequent arrhythmias.

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).